Aerie Pharmaceuticals Inc. announced Wednesday morning it completed enrolling patients in one of its later-stage glaucoma drug testing trials, according a filing with the Securities and Exchange Commission.

The enrollments in “Mercury 2,” Aerie’s second 90-day patient trial with Roclatan, puts Aerie on track to meet its mid-2017 deadline for testing the drug’s efficacy in patients and for testing its superior strength to the two individual drugs that compose it. The trial is a Phase 3 registration trial.

“Should Mercury 2 be successful, we continue to expect to file an NDA for RoclatanTM ophthalmic solution near year-end 2017,” said Vicente Anido, Aerie’s chief executive officer and chairman, in a statement.

The required number of patients for the trial to take place is 690. Aerie reported it exceeded that minimum, although it did not disclose by how many patients.

Aerie Pharmaceuticals is a California-based company with major operations in Durham that focuses on developing drugs for glaucoma treatment. Beginning in the first half of 2017, Aerie plans to begin a Phase 3 registration trial with a third rendition of Roclatan, Mercury 3, intended for the European market. And the company reported strong results from its Mercury 1 trial in September.

Aside from Roclatan, Aerie is also currently testing another major glaucoma drug, Rhopressa, which is one of the two major components of Roclatan. Rhopressa is also in a late-stage Food and Drug Administration trial, and Aerie filed an NDA, or new drug application, for it in September.

Aerie’s stock price fell $1.30, or 3.2 percent, to $39.10 in Wednesday morning trading.